Ocular cicatricial pemphigoid

Current Opinion in Allergy and Clinical Immunology

Volumn 6, Issue 5, 2006, Pages 373-378

  Hingorani, Melanie ^a   Lightman, Susan ^b  

^a HINCHINGBROOKE HOSPITAL   (United Kingdom)

^b MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

Intravenous immunoglobulin; Laminin 5; Mucous membrane pemphigoid; Ocular pemphigoid; Ocular surface reconstruction

Indexed keywords

AUTOANTIBODY; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; KALININ; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID;

ANTIGEN ANTIBODY REACTION; BULLOUS SKIN DISEASE; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE DISEASE; EYE SURGERY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KERATOPROSTHESIS; MUCOUS MEMBRANE PEMPHIGOID; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SYSTEMATIC REVIEW; VISION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; EYE DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PEMPHIGOID, BENIGN MUCOUS MEMBRANE;

EID: 33748553015     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/01.all.0000244799.33734.d4     Document Type: Review

References (41)

1. Hashimoto T. Skin diseases related to abnormality in desmosomes and hemidesmosomes. J Dermtaol Sci 1999; 20:81-84.
2. Darling MR, Daley T. Blistering mucocutaneous diseases of the oral mucosa - a review Part 1 Mucous membrane pemphigoid. J Can Dent Assoc 2005; 71:851-854.
3. Chan LS, Ahmed AR, Ahalt GJ, et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment and prognostic indicators. Arch Dermatol 2002; 138:370-379.
4. Mondino BJ, Brown SI. Ocular cicatricial pemphigoid. Ophthalmology 1981; 88:95-100.
5. Foster CS. Cicatricial pemphigoid. Trans Am Ophthalmol Soc 1986; 84:527-653.
6. Foster CS, Sainz de La Maza M. Ocular cicatricial pemphigoid review. Curr Opin Allergy Clin Immunol 2004; 4:435-439.
7. Elder MJ, Bernauer W, Leonard J, Dart JK. Progression of disease in ocular cicatricial pemphigoid. Br J Ophthalmol 1996; 80:292-296.
8. Thorne JE, Anhalt GJ, Jabs DA. Mucous membrane pemphigoid and pseudopemphigoid. Ophthalmology 2004; 111:45-52.
9. Bernauer W, Wrght P, Dart JK, et al. The conjunctiva in acute and chronic mucous memrane pemphigoid: an immunohistochemical analysis. Ophthalmology 1993; 100:339-346.
10. Elder MJ, Lightman S. The immunological features and pathophysiology of ocular cicatricial pemphigoid. Eye 1994; 8:196-199.
11. Elder MJ, Dart JK, Lightman S. Conjunctival fibrosis in ocular cicatricial pemphigoid: the role of cytokines. Exp Eye Res 1997; 65:165-176.
12. Parisi E, Raghavendra S, Werth VP, Sollecito TP. Modification to the approach of the diagnosis of mucous membrane pemphigoid A case report and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003; 95:182-186.
13. Mondino BJ, Brown SI. Immunosuppressive therapy in ocular cicatricial pemphigoid. Am J Ophthalmol 1983; 96:453-459.
14. Miserocchi E, Baltatzis S, Roque MR, et al. The effect of treatment and its related side effects in patients with severe ocular cicatricial pemphigoid. Ophthalmology 2002; 109:111-118.
15. Vodegel RM, Jonkman MF, Pas HH, de Jonh MC. U-serrated immunodeposition pattern differentiates type VII collagen targeting bullous diseases from other subepidermal bullous autoimmune diseases. Br J Dermatol 2004; 151:112-118.
16. Bagan J, Muzio LL, Scully C. Mucous membrane pemphigoid. Oral Diseases 2005; 11:197-218. A nice review particularly useful for correlation of antigenic heterogeneity with clinical subtypes.
17. Powell AM, Sakuma-Oyama Y, Oyama N, Black MM. Collagen XVII/BP180: a collagenous transmembrane protein and component of the dermoepidermal anchoring complex. Clin Exp Dermatol 2005; 30:682-687.
18. Wozniak K, Kowalewski C. Alterations of basement membrane zone in autoimmune subepidermal bullous diseases. J Dermatol Sci 2005; 40:169-175. Uses high resolution imaging to demonstrate correlation of immune mechanisms with site of tissue seperation.
19. Egan CA, Lazarova Z, Darling TN, et al. Antiepiligrin cicatricial pemphigoid: clinical findings, immunopathogenesis and significant associations. Medicine (Baltimore) 2003; 82:177-186.
20. Shimanovich I, Petersen EE, Weyers W, et al. Subepidermal blistering disease with autoantiboides to both the p200 autoantigen and the α3 chain of laminin 5. J Am Acad Dermatol 2005; 52:S90-S92. Unusual case suggests clinical features may be predictable based on autoantibody profile.
21. Buijsrogge JJA, Pas HH, Jonkman MF. Antiepiligrin cicatricial pemphigoid without mucous membrane involvement. Br J Dermatol 2005; 153:1080-1081.
22. Dainichi T, Takeshita H, Moroi Y, et al. Cicatricial pemphigoid with autoantiboides against the laminin 5 gamma 2 subunit. Eur J Dermatol 2005; 15:189-193. First report of antibodies against γ2 subunit of laminin-5.
23. Coronella G, Amato L, Berti S, et al. Ocular 'nonscarring' mucous membrane pemphigoid associated with antilaminin-5 antibodies. Clin Exp Dermatol 2005; 30:679-681.
24. Oyama N, Setterfield JF, Powell AM, et al. Bullous pemphigoid antigen II (BP180) and its soluble extracellular domains are major autoantigens in mucous membrane pemphigoid: the pathogenic relevance to HLA class II alleles and disease severity. Br J Dermatol 2006; 154:90-98. By examining a large cohort, this study is able to correlate immunological findings with severity.
25. Giomi B, Caproni M, Fabbri P. IL-4 and cellular adhesion molecule (CAM) pathway are involved in cicatricial scarring process. J Dermatol Sci 2005; 38:57-59. Short but interesting argument on the greater likelihood of IL-4, rather than TGF-β, mediated processes for scarring.
26. Bhol KC, Goss L, Kumari S, et al. Autoantibodies to human α6 integrin in patients with oral pemphigoid. J Dent Res 2001; 80:1711-1715.
27. Rashid KA, Stern JNH, Ahmed AR. Identification of an epitope within human integrin α6 subunit for the binding of autoantibody and its role in basement separation in oral pemphigoid. J Immunol 2006; 176:1968-1977. Interesting report which identifies a single integrin α6 epitope in all of 20 patients with oral MMP.
28. Laforest C, Huigol SC, Casson R, et al. Autoimune bulllous diseases. Ocular manifestations and management. Drugs 2005; 65:1767-1779. Very readable update review on the whole range of acquired mucocutaneous bullous disoders.
29. Dart J. Cicatricial pemphigoid and dry eye. Semin Ophthalmol 2005; 20:95-100.
30. Rauz S, Maddison P, Dart JKG. Evaluation of mucous membrane pemphigoid with ocular involvement in young patients. Ophthalmology 2005; 112:1268-1274. Demonstrates important differences in features and outcomes for patients with younger onset OCP.
31. Shiu M, McNab AA. Cictricial entropion and trichiasis in an urban Australian population. Clin Exp Ophthalmology 2005; 33:582-585. This study is a reminder that OCP is a frequently overlooked ocular diagnosis.
32. Bekou V, Thoma-Uszynski S, Wendler O, et al. Detection of laminin 5-specific auto-antibodies in mucous membrane and bullous pemphigoid sera by ELISA. J Invest Dermatol 2005; 124:732-740. Highly sensitive new test for circulating antilaminin antibodies may allow prognostication.
33. Sacher C, Hunzelmann N. Cicatricial pemphigoid (mucous membrane pemphigoid) Current and emerging therapeutic approaches. Am J Clin Dermatol 2005; 6:93-103. Review which highlights the distinct lack of high quality evidence for most therapies in MMP.
34. Thorne JE, Jabs DA, Qazi FA, et al. Mycophenolate mofetil therapy for inflammatory eye disease. Ophthalmology 2005; 112:1472-1477.
35. Tellier Z. Intravenous immunoglobulin in eye involvement. Clin Rev Allergy Immunol 2005; 29:295-306.
36. Sami N, Letko E, Androudi S, et al. Intravenous immunoglobulin therapy in patients with ocular cictricial pemphigoid. A long-term follow-up. Ophthalmology 2004; 111:1380-1382.
37. Daoud Y, Amin KG, Mohan K, Ahmed AR. Cost of intravenous immunoglobulin therapy versus conventional immunosuppressive therapy in patients with mucous membrane pemphigoid: a preliminary study. Ann Pharmacother 2005; 39:2003-2008. Makes an interesting argument that analysis of the real cost of the expensive IVIg needs to include savings gained by in the avoidance of immunosuppressive side effects.
38. Tseng SCG, Di Pascuale MA, Liu DT-S, et al. Intraoperative mitomycin C and amniotic membrane transplantation for fornix reconstruction in severe cicatricial ocular surface diseases. Ophthalmology 2005; 112:896-903. Shows step by step how to perform this procedure.
39. Yesudian PD, Armstrong S, Cawood JI, et al. Br J Dermatol 2005; 153:692-694.
40. Inatomi T, Nakamura T, Koizumi N, et al. Midterm results on ocular surface reconstruction using cultivated autologous oral mucosal epithelial transplantation. Am J Ophthalmol 2006; 141:267-275. Highlights one of the new techniques emerging for ocular surface reconstruction in the absence of host limbal stem cells.
41. Falcinelli G, Falsini B, Taloni M, et al. Modified osteo-odontol- keratoprosthesis for treatment of corneal blindness. Long-term anatomical and functional outcomes in 181 cases. Arch Ophthalmol 2005; 123:1319-1329.